Abstract
Background
Non-alcoholic fatty liver disease (NAFLD) is the main common cause of chronic liver disease. The aim of this study is to evaluate the effect of Shilajit, a medicine of Ayurveda, on the liver damage caused by NAFLD.
Materials and methods
Forty male Wistar rats, after being established as fatty liver models by feeding a high-fat diet (HFD, 12 weeks), were divided randomly into five groups as follows: control (standard diet), vehicle (HFD + distilled water), high-dose Shilajit (HFD + 250 mg/kg Shilajit), low-dose Shilajit (HFD + 150 mg/kg Shilajit) and pioglitazone (HFD + 10 mg/kg pioglitazone). The serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), triglycerides (TG), total cholesterol (TC), low-density lipoprotein (LDL), glucose and liver glutathione peroxidase (GPx), superoxide dismutase (SOD) activity, malondialdehyde (MDA) levels, liver weight, and histopathological manifestation outcomes were measured after the 2-week intervention.
Results
Shilajit treatment significantly reduced the values of AST and ALT, TG, TC, LDL, glucose, liver weight, and steatosis, and instead, increased high-density lipoprotein (HDL) compared with the vehicle group (p < 0.05). Further, Shilajit treatment improved the adverse effects of HFD-induced histopathological changes in the liver as compared with the vehicle group (p < 0.001). MDA level and GPx activity increased but SOD activity decreased in the vehicle group compared with the control group (p < 0.05), while treatment with Shilajit restored the antioxidant/oxidant balance toward a significant increase in the antioxidant system in the Shilajit group (p < 0.05).
Conclusions
These findings suggest that Shilajit improved the histopathological NAFLD changes in the liver and indicated the potential applicability of Shilajit as a potent agent for NAFLD treatment.
Acknowledgment
This work is part of the Ph.D. thesis of Ms. Ghezelbash at the Department of Physiology.
Author statement
Research funding: The present study was financially supported by the Physiology Research Center, Kerman University of Medical Sciences, Kerman, Iran.
Conflict of interest: All the authors declare no conflicts of interest.
Informed consent: Not applicable.
Ethical approval: This study was approved by the Medical Ethics Committee of Kerman University of Medical Sciences (Approval No: IR. KMU. REC. 1394. 681).
References
[1] Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med. 2017;15:45.10.1186/s12916-017-0806-8Search in Google Scholar PubMed PubMed Central
[2] Farrell GC, Wong VW, Chitturi S. NAFLD in Asia – as common and important as in the West. Nat Rev Gastroenterol Hepatol. 2013;10:307–18.10.1038/nrgastro.2013.34Search in Google Scholar PubMed
[3] Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of non-alcoholic fatty liver disease–meta-analytic assessment of prevalence, incidence and outcomes. Hepatology. 2016;64:1388-9.10.1002/hep.28584Search in Google Scholar PubMed
[4] Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2002;17(Suppl):S186–90.10.1046/j.1440-1746.17.s1.10.xSearch in Google Scholar PubMed
[5] Banini BA, Sanyal AJ. Nonalcoholic fatty liver disease: epidemiology, pathogenesis, natural history, diagnosis, and current treatment options. Clin Med Insights Ther. 2016;8:75.10.4137/CMT.S18885Search in Google Scholar PubMed PubMed Central
[6] Yki-Jarvinen H. Diagnosis of non-alcoholic fatty liver disease (NAFLD). Diabetologia. 2016;59:1104–11.10.1007/s00125-016-3944-1Search in Google Scholar PubMed
[7] Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011;53:1874–82.10.1002/hep.24268Search in Google Scholar PubMed
[8] Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865–73.10.1002/hep.21327Search in Google Scholar PubMed
[9] Kopelman PG. Obesity as a medical problem. Nature. 2000;404:635–43.10.1038/35007508Search in Google Scholar PubMed
[10] Kopelman PG, Finer N. Reply: is obesity a disease? Int J Obes Relat Metab Disord. 2001;25:1405–6.10.1038/sj.ijo.0801791Search in Google Scholar PubMed
[11] Sharma P, Jha J, Shrinivas V, Dwivedi LK, Suresh P, Sinha M. Shilajit: evalution of its effects on blood chemistry of normal human subjects. Anc Sci Life. 2003;23:114–9.Search in Google Scholar
[12] Agarwal SP, Khanna R, Karmarkar R, Anwer MK, Khar RK. Shilajit: a review. Phytother Res. 2007;21:401–5.10.1002/ptr.2100Search in Google Scholar
[13] Gangwar SS, Thakur R, Sharma R, Tilak A. Shilajit a medicinal mystery to cure the un-cure disease. Imperial J Interdisciplinary Res. 2016;3:1544–7.Search in Google Scholar
[14] Stohs SJ. Safety and efficacy of shilajit (mumie, moomiyo). Phytother Res. 2014;28:475–9.10.1002/ptr.5018Search in Google Scholar
[15] Goel RK, Banerjee RS, Acharya SB. Antiulcerogenic and antiinflammatory studies with shilajit. J Ethnopharmacol. 1990;29:95–103.10.1016/0378-8741(90)90102-YSearch in Google Scholar
[16] Deng XQ, Chen LL, Li NX. The expression of SIRT1 in nonalcoholic fatty liver disease induced by high-fat diet in rats. Liver Intern. 2007;27:708–15.10.1111/j.1478-3231.2007.01497.xSearch in Google Scholar PubMed
[17] Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.10.1002/hep.20701Search in Google Scholar PubMed
[18] Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the World. Clin Liver Dis. 2016;20:205–14.10.1016/j.cld.2015.10.001Search in Google Scholar PubMed
[19] Ji J, Zhang L, Wang P, Mu YM, Zhu XY, Wu YY, et al. Saturated free fatty acid, palmitic acid, induces apoptosis in fetal hepatocytes in culture. Exp Toxicol Pathol. 2005;56:369–76.10.1016/j.etp.2005.02.003Search in Google Scholar PubMed
[20] de Almeida IT, Cortez-Pinto H, Fidalgo G, Rodrigues D, Camilo ME. Plasma total and free fatty acids composition in human non-alcoholic steatohepatitis. Clin Nutr. 2002;21:219–23.10.1054/clnu.2001.0529Search in Google Scholar PubMed
[21] Malhi H, Gores GJ. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis. 2008;28:360–9.10.1055/s-0028-1091980Search in Google Scholar PubMed PubMed Central
[22] Akazawa Y, Cazanave S, Mott JL, Elmi N, Bronk SF, Kohno S, et al. Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis. J Hepatol. 2010;52:586–93.10.1016/j.jhep.2010.01.003Search in Google Scholar PubMed PubMed Central
[23] Perry IJ, Wannamethee SG, Shaper AG. Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care. 1998;21:732–7.10.2337/diacare.21.5.732Search in Google Scholar
[24] Ghosal S, Bhattacharya SK. Antioxidant defense by native and processed shilajit – a comparative study. Indian J Chem. 1996;35B:127–32.Search in Google Scholar
[25] Tripathi YB, Shukla S, Chaurasia S, Chaturvedi S. Antilipid peroxidative property of Shilajit. Phytother Res. 1996;10:269–70.10.1002/(SICI)1099-1573(199605)10:3<269::AID-PTR817>3.0.CO;2-3Search in Google Scholar
[26] Trivedi N, Mazumdar B, Bhatt J, Hemavathi K. Effect of shilajit on blood glucose and lipid profile in alloxan-induced diabetic rats. Indian J Pharmacol. 2004;36:373.Search in Google Scholar
[27] Hikita H, Takehara T, Shimizu S, Kodama T, Li W, Miyagi T, et al. Mcl-1 and Bcl-xL cooperatively maintain integrity of hepatocytes in developing and adult murine liver. Hepatology. 2009;50:1217–26.10.1002/hep.23126Search in Google Scholar
[28] Kececi M, Akpolat M, Gulle K, Gencer E, Sahbaz A. Evaluation of preventive effect of shilajit on radiation-induced apoptosis on ovaries. Arch Gynecol Obstet. 2016;293:1255–62.10.1007/s00404-015-3924-6Search in Google Scholar
[29] Bhattacharya SK, Sen AP, Ghosal S. Effects of shilajit on biogenic free radicals. Phytotherapy Res. 1995;9:56–9.10.1002/ptr.2650090113Search in Google Scholar
[30] Jarukamjorn K, Jearapong N, Pimson C, Chatuphonprasert W. A high-fat, high-fructose diet induces antioxidant imbalance and increases the risk and progression of nonalcoholic fatty liver disease in mice. Scientifica. 2016;2016.10.1155/2016/5029414Search in Google Scholar
[31] Ismail NA, Okasha SH, Dhawan A, Abdel-Rahman AO, Shaker OG, Sadik NA. Antioxidant enzyme activities in hepatic tissue from children with chronic cholestatic liver disease. Saudi J Gastroenterol. 2010;16:90.10.4103/1319-3767.61234Search in Google Scholar
[32] Crawford A, Coombes JS, Kunde DA, Ahuja KD, Robertson LK, Ball MJ, et al. Glutathione peroxidase, superoxide dismutase and catalase activities in children with chronic hepatitis. Adv Biosci Biotechnol. 2011;26:2806–13.10.1093/ndt/gfq828Search in Google Scholar
[33] Chrobot AM, Szaflarska-Szczepanik A, Drewa G. Antioxidant defense in children with chronic viral hepatitis B and C. Med Sci Monit. 2000;6:713–8.Search in Google Scholar
[34] Chance B, Sies H, Boveris A. Hydroperoxide metabolism in mammalian organs. Physiol Rev. 1979;59:527–605.10.1152/physrev.1979.59.3.527Search in Google Scholar
[35] Ighodaro O, Akinloye O. First line defence antioxidants-superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX): their fundamental role in the entire antioxidant defence grid. Alexandria J Med. 2018;54:287–93.10.1016/j.ajme.2017.09.001Search in Google Scholar
[36] Carrasco-Gallardo C, Guzman L, Maccioni RB. Shilajit: a natural phytocomplex with potential procognitive activity. Int J Alzheimers Dis. 2012;2012:674142.10.1155/2012/674142Search in Google Scholar
[37] Borek C. Dietary antioxidants and human cancer. Integr Cancer Ther. 2004;3:333–41.10.1177/1534735404270578Search in Google Scholar PubMed
© 2020 Walter de Gruyter GmbH, Berlin/Boston
